Utilization of MG-ADL in myasthenia gravis clinical research and care.

"CONFLICT OF INTEREST This review was funded by argenx. S. Muppidi has served as a paid consultant for Alexion Pharmaceuticals, argenx, and Ra Pharmaceuticals. N. Silvestri has served as a paid consultant for Alexion Pharmaceuticals, argenx, and UCB. R. Tan and K. Riggs are employees of Xcenda, which was paid by argenx to conduct the literature review upon which this manuscript is based and to help prepare the manuscript. T. Leighton is a former employee of and owns stock in argenx. G. Phillips is a current employee of and owns stock in argenx. The study concept was initiated by T. Leighton. S. Muppidi and N. Silvestri provided guidance during the review process on concepts that should be addressed. R. Tan and K. Riggs conducted the review. S. Muppidi and N. Silvestri provided input on the results and interpretation of the review. G. Phillips provided input on measurement and psychometric concepts in the review. All authors contributed to the writing, review processes, and final approval of the manuscript."